Global Capecitabine Market: Overview

The global capecitabine market size was significantly robust in 2020 and is expected to register a steadily inclining revenue CAGR over the forecast period. Consistently steady market revenue is mainly attributed to rising prevalence of cancer worldwide. As per the World Health Organization (WHO), cancer accounted for around 10 million deaths worldwide in 2020, with nearly 685,000, 935,000, and 830,000 deaths due to breast cancer, Colorectal Cancer, and Liver Cancer, respectively. Global market growth is further driven by increasing usage of capecitabine (usually in combination with other drugs) in cancer treatment, rise in R&D activities for cancer therapeutics, and increasing number of cancer awareness programs by various private and government organizations such as Cancer Research UK and American Cancer Society.

Capecitabine is a chemotherapy medication used in treatment of different cancer types, including breast cancer, colorectal cancer, and Gastric Cancer. The drug – which is most widely sold under the brand Xeloda – is often combined with docetaxel (another common chemotherapy drug) to treat breast cancer. Capecitabine is part of a group of antimetabolites (anti-cancer drugs), called fluoropyrimidines, and it is administered orally. In 1998, the drug was granted regulatory approval for medical use. For breast cancer treatment, capecitabine is used as a metastatic or monotherapy; while, in cases of colorectal cancer, the drug is mostly used as neoadjuvant therapy with radiation.

Global Capecitabine Market: Dynamics
Drivers: Growing use of capecitabine in treatment of breast cancer

Capecitabine is approved as an advanced medication for metastatic breast cancer. Capecitabine, in combination with taxane-based chemotherapy agents such as docetaxel (taxotere) and paclitaxel (taxol), is proven to be effective and well-tolerated in breast cancer patients. Therefore, increasing burden of breast cancer worldwide and rising awareness among the patient regarding the advantages are factors expected to boost market growth going ahead.

Restraints: Side-effects associated with capecitabine

Growth of the global capecitabine market is significantly hampered due to various side-effects associated with capecitabine. Some serious side-effects of the drug include anemia, chest pain, diarrhea, vomiting, weakness, blood clotting problems, and cardiac-related issues such as cardiomyopathy. Kidney disease, DPD deficiency, and pregnancy are among other common contraindications of the drug.

Global Capecitabine Market: Indication Outlook

The breast cancer segment is expected to account for largest revenue share in the global capecitabine market over the forecast period. Rising prevalence of breast cancer, increasing need for early cancer diagnosis, and ongoing R&D activities for breast cancer treatment are factors driving revenue growth of this segment. 

Global Capecitabine Market: Regional Outlook

The capecitabine market in North America is expected to account for largest revenue share over the forecast period. Surging prevalence of different types of cancers, including breast cancer and colorectal cancer, in countries in the region, rising prevalence of unhealthy lifestyle-induced diseases such as obesity and hypertension, rapid increase in the global geriatric population, and increasing government funding for cancer research are major factors expected to fuel growth of the North America market over the forecast period.

Companies Profiled in the Report:

Cipla Inc., Genentech, Inc., F. Hoffmann-La Roche, Ranbaxy Laboratories Ltd., Teva Pharma B.V., Mylan N.V., Sandoz, Fresenius SE & Co. KGaA, Zentiva N.V., Accord Healthcare Ltd., and Dr. Reddy Laboratories Ltd. are some of the major companies operating in the global capecitabine market.

In February 2021, Dr. Reddy’s Laboratories launched Capecitabine Tablets, USP, which is a therapeutic generic version of Xeloda Tablets, following approval by the U. S. FDA.

In April 2020, Seattle Genetics announced U.S. FDA approval for its TUKYSA (Tucatinib) tablets indicated for breast cancer. TUKYSA, which is a tyrosine kinase inhibitor, along with Roche’s capecitabine and trastuzumab, is specifically indicated for metastatic HER2-positive breast cancer.

Report Scope & Segments Covered in the Report:

This report offers historical data points and forecasts and revenue growth at a global, regional, and country level, and provides analysis, industry trends, and consumption pattern details for each region, major country, and segment from 2018 to 2028. The global capecitabine market report includes industry trends, drivers, restraints, opportunities, threats, market strategies, segment revenue, and market share contribution by each regional and country market. In addition, the report offers industry analysis and competitive landscape, company financials, and impact analysis. The report includes a detailed view of the global capecitabine market, along with changing dynamics and trends, scenarios, detailed market and regional segmentation, regional landscape, analysis and evaluation, major investments, product offerings, product launches, and details of historical, current, and projected revenues.

For the purpose of this report, the global capecitabine market is segmented based on indication, drug type, drug formulation, end-use, distribution channel, and region:

Indication Outlook (Revenue, USD Billion; 2018-2028)

  • Breast Cancer
  • Colorectal Cancer
  • Gastric Cancer
  • Others

Drug Type Outlook (Revenue, USD Billion; 2018-2028)

  • Branded
  • Generic

Drug Formulation Outlook (Revenue, USD Billion; 2018-2028)

  • Tablets
  • Capsules

End-use Outlook (Revenue, USD Billion; 2018-2028)

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

Distribution Channel Outlook (Revenue, USD Billion; 2018-2028)

  • Hospital Pharmacies
  • Retail Stores
  • Online Pharmacies
  • Others

Region Outlook (Revenue, USD Billion; 2018-2028)

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Benelux
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Singapore
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • South Africa
    • Rest of Middle East & Africa

REQUEST SAMPLE REPORT

Get Free Sample Report

REQUEST SAMPLE REPORT

REQUEST FOR CUSTOMIZATION

Tailor-make Your Research

REQUEST CUSTOMIZATION

Key questions answered by the report